Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Head and Neck Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Salivary Gland Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Tongue Neoplasms 5Rectal Neoplasms 3Pancreatic Neoplasms 3Esthesioneuroblastoma, Olfactory 3Colonic Neoplasms 3Carcinoma, Squamous Cell 3Pharyngeal Neoplasms 2Mouth Neoplasms 2Laryngeal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Tonsillar Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Parotid Neoplasms 1Paranasal Sinus Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1

Interventions

Cisplatin 35Radiotherapy 21Magnetic Resonance Spectroscopy 19Cetuximab 17Specimen Handling 15pembrolizumab 13Carboplatin 13Radiotherapy, Intensity-Modulated 12Fluorouracil 12Docetaxel 121,2-diaminocyclohexaneplatinum II citrate 10Radiation 9Platinum 9Surgical Procedures, Operative 8Paclitaxel 8Drug Therapy 7Biopsy 7Taxes 5Surveys and Questionnaires 5toripalimab 4X-Rays 4Standard of Care 4Fluorodeoxyglucose F18 4Celecoxib 4(225)Ac-DOTA-c(RGDyK) 4cemiplimab 3Nutritional Status 3Laser Therapy 3Interviews as Topic 3Immunohistochemistry 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Laryngeal Neoplasms × Erlotinib Hydrochloride × Head & Neck × Clear all
NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Mayo Clinic

Phase 2 Recruiting
25 enrolled
Head & Neck

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT00970502 2017-04-10

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
15 enrolled 16 charts
Head & Neck

Head and Neck Neoplasms, Laryngeal Neoplasms, Paranasal Sinus Neoplasms, Pharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡